Impact of Baseline Visual Acuity on Outcomes in DME
October 1, 2024 • Retinal Diseases Content Hub
Sean Adrean, MD, Retina Consultants of Orange County, describes results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of baseline visual acuity on visual and anatomic outcomes in patients with diabetic macular edema. Baseline best-corrected visual acuity did not impact meaningful visual and anatomic improvements in eyes treated with aflibercept 8 mg. Dr Adrean also noted that whether or not patients have 20/50 vision or worse or 20/40 or better vision, they can be treated with these extending dosing intervals.
